DNLI NASDAQ
Denali Therapeutics Inc.
1W: +1.5%
1M: -8.4%
3M: -19.4%
YTD: +18.1%
1Y: +20.4%
3Y: +4.9%
5Y: -56.6%
$19.22
+0.56 (+3.00%)
Weekly Expected Move ±5.8%
$16
$17
$18
$19
$21
Credit Risk of going bust: lower than 80% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Denali Therapeutics Inc. would be worth roughly what it owes.
Total debt $27.5M against a stock market value of $3.07B.
Distance to default 9.60 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $13.8M (short-term plus half of long-term), stock volatility 55.5%; Altman Z'' -3.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Denali Therapeutics Inc. would be worth roughly what it owes.
Total debt $27.5M against a stock market value of $3.07B.
Distance to default 9.60 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $13.8M (short-term plus half of long-term), stock volatility 55.5%; Altman Z'' -3.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Denali Therapeutics Inc. (DNLI) – What Are Analysts Saying About This Stock?
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Bank of America Corp DE Buys New Position in Denali Therapeutics Inc. $DNLI
Engineers Gate Manager LP Boosts Stock Position in Denali Therapeutics Inc. $DNLI
WINTON GROUP Ltd Decreases Position in Denali Therapeutics Inc. $DNLI
BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLI
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics Inc. $DNLI Shares Acquired by California State Teachers Retirement System
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of “Moderate Buy” by Brokerages
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg - GuruFocus
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits
Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI) - simplywall.st
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - Yahoo Finance
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A - Stock Titan
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - simplywall.st
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI) - TradingView
DNLI Forecast — Price Target — Prediction for 2027 - TradingView
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
Denali to Sell Priority Review Voucher for $195M Cash Boost
Denali to Sell Priority Review Voucher for $195M Cash Boost
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names - Yahoo Finance
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos - Yahoo Finance
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Parkinson’s drug from Biogen, Denali comes up short
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Yahoo Finance
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights - Yahoo Finance
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in - Yahoo Finance
B. Metzler seel. Sohn & Co. AG Makes New $1.84 Million Investment in Denali Therapeutics Inc. $DNLI
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Denali Therapeutics Inc. $DNLI Shares Acquired by Baillie Gifford & Co.
Q3 EPS Forecast for Denali Therapeutics Lifted by Analyst
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
Denali Stock Falls as Partner Takeda Ends Collaboration Deal - Yahoo Finance
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts
Takeda exits dementia drug pact, Denali targets trial data by 2026 end - Stock Titan
Is It Time To Revisit Denali Therapeutics (DNLI) After Recent Share Price Pullback - simplywall.st
Equities Analysts Offer Predictions for DNLI FY2027 Earnings
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA Nod - What's Changed - Yahoo Finance
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up - Yahoo Finance
Denali gains on FDA approval of lead asset
Cantor Fitzgerald L. P. Makes New $653,000 Investment in Denali Therapeutics Inc. $DNLI
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
$DNLI stock is up 7% today. Here's what we see in our data. - Quiver Quantitative
HC Wainwright Brokers Raise Earnings Estimates for DNLI
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali Therapeutics GAAP EPS of -$0.73 in-line
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
Head to Head Comparison: Ultragenyx Pharmaceutical (NASDAQ:RARE) and Denali Therapeutics (NASDAQ:DNLI)
SG Americas Securities LLC Invests $555,000 in Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Analysts
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of “Buy” by Brokerages
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? - Yahoo Finance